Category: Clinical Trial Update Region: Asia · India Company: Astrazeneca Pharma India Ltd

AstraZeneca dapagliflozin meets primary endpoint in DELIVER phase III trial, reduces CVD fatality

AstraZeneca dapagliflozin meets primary endpoint in DELIVER phase III trial, reduces CVD fatality
AstraZeneca

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!